Alexander J. Valvezan

This paper identifies IMPDH as a therapeutic target in PTEN-deficient T-ALL, showing IMPDH inhibitors selectively kill these cells and extend survival in mouse models.

This study shows mTORC1 activity oscillates during the cell cycle, peaks in S and G2, and is lowest in mitosis and G1, with distinct regulatory mechanisms and functional consequences.